Mazdutide
GLP-1 / glucagon dual receptor agonist (IBI362 / LY3305677)
Overview
Mazdutide, carrying development codes IBI362 (Innovent) and LY3305677 (Eli Lilly), is an investigational dual co-agonist hitting both the GLP-1 receptor and the glucagon receptor. Receptor scope is what marks it inside the multi-agonist landscape: it sits between the GIP/GLP-1 dual agonist Tirzepatide and the GIP/GLP-1/glucagon tri-agonist Retatrutide, engaging the GLP-1 and glucagon arms only, with no GIP component. This positioning makes the molecule the right tool when research needs to isolate the glucagon-pathway contribution from the GIP contribution inside the dual / tri-agonist family. Development is led by Innovent Biologics in China under licence from Eli Lilly, currently in the Phase 3 DREAMS program for chronic weight management and T2DM; Chinese NMPA approval is on a faster track than Western markets. For research and pre-clinical buyers, Vialdyne releases Mazdutide acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The batch COA covers RP-HPLC peak integration, ESI-MS identity, Karl Fischer water, and counter-ion quantitation. LC-MS/MS sequence verification is offered as a documented add-on and is the recommended test at first-time pharmacy qualification: the close structural similarity within the dual-agonist class means cross-supplier identity confusion is an operationally real risk if mass-spec is the only identity gate. The 10 mg standard fill fits bench-scale aliquot work; larger fills for extended programs are scoped under change-control.
Who buys this, and why
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Primary buyer fit: academic and contract research laboratories.
Specifications
- CAS
- 2252403-56-6
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 10 mg
- MOQ
- On request
- Lead time
- 14–21 days
- Storage
- -20°C, protect from light
Documentation available on request
- Certificate of Analysis (COA)
- HPLC Chromatogram
- Mass-spec identity (ESI-MS)
- Counter-ion / residual solvent
- Bacterial endotoxin (LAL, USP <85>)
- Microbial limits (USP <61>/<62>)
- Stability data on request
- 503A / 503B documentation support
Regulatory note
Investigational compound in Phase 3 development (Innovent / Eli Lilly); not approved as a finished drug at the time of writing. Supplied for research use only. CAS commonly cited but should be verified per batch COA.
Frequently asked questions
How does Mazdutide compare with Tirzepatide and Retatrutide mechanistically?▾
All three are multi-receptor incretin-pathway peptides, but the receptor coverage map is different across the three. Tirzepatide is GIP + GLP-1; Mazdutide is GLP-1 + glucagon; Retatrutide is GIP + GLP-1 + glucagon. The presence or absence of the glucagon receptor arm is the mechanistic dividing line, glucagon-receptor agonism contributes hepatic energy expenditure on top of the incretin-driven glycaemic and weight effects. Mazdutide isolates the GLP-1 + glucagon mechanism, which is useful for research designed to separate the glucagon contribution from the GIP contribution within the broader dual / tri-agonist family. Mechanistic equivalence between any pair of molecules in this class cannot be assumed, the readouts diverge enough to matter at the experimental-design level. The [GLP-1 class comparison article](/insights/glp-1-class-comparison-tirzepatide-retatrutide-mazdutide-survodutide) covers the full side-by-side.
What's the development partnership behind Mazdutide, and what regulatory timeline applies?▾
Innovent Biologics (China) is leading development under licence from Eli Lilly, which reflects Eli Lilly's broader strategy of licensing certain metabolic-pipeline assets to regional partners for China-focused development while retaining global rights to its own internal assets like Retatrutide. The Mazdutide Phase 3 program (DREAMS-1 through DREAMS-3) has reported Phase 3 readouts across weight-management and type 2 diabetes endpoints. Chinese NMPA approval is expected to precede Western approval by a meaningful margin; buyers operating in China can begin to reference local approval-pathway documentation as it lands, while buyers in EU and US markets should continue to treat Mazdutide as investigational until further notice.
Should I source Mazdutide or Survodutide for GLP-1/glucagon dual-agonist research?▾
Receptor coverage is identical between the two (GLP-1R + GCGR, no GIP), so the choice comes down to which sponsor's clinical data set your work needs to align with. Research benchmarking against Chinese clinical data points to Mazdutide (Innovent / Eli Lilly, China-focused development). Research benchmarking against EU or US clinical data points to Survodutide (Boehringer Ingelheim / Zealand Pharma, global development). The two molecules differ in peptide sequence and in lipidation chemistry, so do not treat them as interchangeable in any analytical or research context, confirm exact identity per batch COA before committing to a substitution.
Related peptides
Buyers who view Mazdutide also ask about:
Survodutide
≥99.0%GLP-1 / glucagon dual receptor agonist (BI 456906)
- CAS
- 2365457-03-9
- Vial
- 10 mg
Retatrutide
≥99.0%GIP / GLP-1 / glucagon tri-agonist
- CAS
- 2381089-83-2
- Vial
- 5 mg–60 mg
Tirzepatide
≥99.0%GIP / GLP-1 dual receptor agonist
- CAS
- 2023788-19-2
- Vial
- 2 mg–120 mg